Physicians' Academy for Cardiovascular Education

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD (Leipzig, Germany), prof. Chris Packard, PhD (Glasgow, UK) and prof. Wouter Jukema, MD, PhD (Leiden, The Netherlands)

Transcript

Show transcript

Educational information

This discussion is part of a series titled "CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl".

Faculty

Prof. Ulrich Laufs, MD, PhD, is professor of cardiology at the University of Leipzig Medical Center in Germany.

Prof. Chris Packard, PhD, Research and Development Director, NHS Greater Glasgow & Clyde Health Board; Honorary professor of vascular biochemistry, University of Glasgow, Scotland, United Kingdom

Prof. J. Wouter Jukema, MD, PhD, is Professor of Cardiology at the Leiden University Medical Center in Leiden, The Netherlands.

Disclosures

The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant received from Amarin.

Watch the presentations of this symposium

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: